Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tedizolid Phosphate

FDA-approved product (tablet, oral), marketed as Sivextro.

Registered studies
37
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tedizolid Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antibacterials
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX11

Repurposing investigation

Tedizolid Phosphate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA71.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tedizolid Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tedizolid Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

    NCT02066402 · start 2014-03-04

    Registered record
    Registry ID
    NCT02066402
    Conditions
    Bacterial Infections
    Interventions
    Tedizolid (BAY119-2631); Placebo Tedizolid (BAY119-2631); Linezolid; Placebo Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03-04
    Completion
    2016-04-18
    Enrolment
    598

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionTedizolid (BAY119-2631); Placebo Tedizolid (BAY119-2631); Linezolid; Placebo Linezolid
    PhasePhase 3
    Registry statusCompleted

  • Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

    NCT02019420 · start 2014-01-06

    Registered record
    Registry ID
    NCT02019420
    Conditions
    Pneumonia
    Interventions
    Tedizolid phosphate; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-01-06
    Completion
    2018-06-22
    Enrolment
    726

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionTedizolid phosphate; Linezolid
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

    NCT01967225 · start 2013-11-23

    Registered record
    Registry ID
    NCT01967225
    Conditions
    Skin Diseases, Infectious
    Interventions
    Tedizolid Phosphate (Sivextro, BAY1192631); Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11-23
    Completion
    2016-10-28
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious
    InterventionTedizolid Phosphate (Sivextro, BAY1192631); Linezolid
    PhasePhase 3
    Registry statusCompleted

  • A Phase 1, Open-Label, 10 Day Safety Study

    NCT01623401 · start 2012-05-17

    Registered record
    Registry ID
    NCT01623401
    Conditions
    Healthy Subjects
    Interventions
    TR-701 FA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05-17
    Completion
    2012-08-24
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionTR-701 FA
    PhasePhase 1
    Registry statusCompleted

  • A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

    NCT01577459 · start 2012-04-23

    Registered record
    Registry ID
    NCT01577459
    Conditions
    Healthy Subjects
    Interventions
    TR-701 FA with PSE; TR-701 FA Placebo with PSE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04-23
    Completion
    2012-06-15
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionTR-701 FA with PSE; TR-701 FA Placebo with PSE
    PhasePhase 1
    Registry statusCompleted

  • A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

    NCT01519778 · start 2012-02-15

    Registered record
    Registry ID
    NCT01519778
    Conditions
    Major Cutaneous Abscess; Cellulitis; Erysipelas
    Interventions
    TR701 FA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-02-15
    Completion
    2012-08-27
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Cutaneous Abscess; Cellulitis; Erysipelas
    InterventionTR701 FA
    PhasePhase 2
    Registry statusCompleted

  • A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

    NCT01539473 · start 2012-02

    Registered record
    Registry ID
    NCT01539473
    Conditions
    Healthy Volunteers
    Interventions
    TR-701 FA with Tyramine; Placebo-controlled withTyramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2012-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTR-701 FA with Tyramine; Placebo-controlled withTyramine
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

    NCT01496677 · start 2012-01-17

    Registered record
    Registry ID
    NCT01496677
    Conditions
    Healthy Subjects
    Interventions
    TR-701 FA 200 mg; TR-701 FA 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01-17
    Completion
    2012-02-28
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionTR-701 FA 200 mg; TR-701 FA 200 mg
    PhasePhase 1
    Registry statusCompleted

  • A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

    NCT01461460 · start 2011-11-28

    Registered record
    Registry ID
    NCT01461460
    Conditions
    Healthy Volunteer
    Interventions
    TR-701 FA 1200 mg; Moxifloxacin 400 mg; TR-701 FA 200 mg plus Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11-28
    Completion
    2011-12-23
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionTR-701 FA 1200 mg; Moxifloxacin 400 mg; TR-701 FA 200 mg plus Placebo; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

    NCT01452828 · start 2011-10

    Registered record
    Registry ID
    NCT01452828
    Conditions
    Renal Impairment
    Interventions
    TR-701 FA single infusion; TR-701 FA; TR-701 FA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionTR-701 FA single infusion; TR-701 FA; TR-701 FA
    PhasePhase 1
    Registry statusCompleted

  • TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

    NCT01421511 · start 2011-09-15

    Registered record
    Registry ID
    NCT01421511
    Conditions
    Skin and Subcutaneous Tissue Bacterial Infections
    Interventions
    TR-701 FA; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09-15
    Completion
    2013-01-10
    Enrolment
    666

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin and Subcutaneous Tissue Bacterial Infections
    InterventionTR-701 FA; Linezolid
    PhasePhase 3
    Registry statusCompleted

  • A PK and Safety Study in Subjects With Hepatic Impairment

    NCT01431833 · start 2011-08

    Registered record
    Registry ID
    NCT01431833
    Conditions
    Hepatic Impairment
    Interventions
    TR-701 FA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-05
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionTR-701 FA
    PhasePhase 1
    Registry statusCompleted

  • Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

    NCT01271998 · start 2010-12-08

    Registered record
    Registry ID
    NCT01271998
    Conditions
    Bacterial Infection
    Interventions
    TR-701 FA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-12-08
    Completion
    2011-01-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionTR-701 FA
    PhasePhase 1
    Registry statusCompleted

  • Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

    NCT01442831 · start 2010-09-09

    Registered record
    Registry ID
    NCT01442831
    Conditions
    Healthy
    Interventions
    Human ADME
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09-09
    Completion
    2010-09-22
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionHuman ADME
    PhasePhase 1
    Registry statusCompleted

  • TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

    NCT01170221 · start 2010-08-15

    Registered record
    Registry ID
    NCT01170221
    Conditions
    Skin and Subcutaneous Tissue Bacterial Infections
    Interventions
    TR-701 FA; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08-15
    Completion
    2011-09-30
    Enrolment
    667

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin and Subcutaneous Tissue Bacterial Infections
    InterventionTR-701 FA; Linezolid
    PhasePhase 3
    Registry statusCompleted